<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药魔方Med | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-18T13:16:05+08:00</updated>
  <subtitle>Best Evidence, Best Benefit</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>亚组分析，失败临床研究的一线生机？</title>
    <updated>2020-12-18T09:46:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-18:/s/0ZbFIz44wkfh7x6SI81mig</id>
    <link href="https://mp.weixin.qq.com/s/0ZbFIz44wkfh7x6SI81mig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医药魔方Med招聘：医学编辑</title>
    <updated>2020-12-16T11:09:47+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-16:/s/8UT2_hnDJYpagfK3pfKrGg</id>
    <link href="https://mp.weixin.qq.com/s/8UT2_hnDJYpagfK3pfKrGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>五花八门的临床研究终点，傻傻分不清楚？</title>
    <updated>2020-12-15T12:29:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-15:/s/jhRO218qQ5qn_FaAP83Vtw</id>
    <link href="https://mp.weixin.qq.com/s/jhRO218qQ5qn_FaAP83Vtw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>阿斯利康69亿美元收购的DS-8201，临床试验设计有何奥秘？</title>
    <updated>2020-12-14T11:41:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-14:/s/9qhy2MSrPRIZEcEWWxO19A</id>
    <link href="https://mp.weixin.qq.com/s/9qhy2MSrPRIZEcEWWxO19A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球肿瘤新药重磅临床进展 | 2020年11月</title>
    <updated>2020-12-10T11:07:02+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/IzQeaPkfnlwtoFW3UJBzJQ</id>
    <link href="https://mp.weixin.qq.com/s/IzQeaPkfnlwtoFW3UJBzJQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>11月肺癌月报 | 重磅研究、高分综述、新开试验，一文洞悉最新进展！</title>
    <updated>2020-12-08T10:38:57+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/DRM1Feu5J6gxFquUhecuLw</id>
    <link href="https://mp.weixin.qq.com/s/DRM1Feu5J6gxFquUhecuLw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>韩宝惠教授盘点2020年肺癌靶向治疗进展</title>
    <updated>2020-12-07T12:17:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/C663GI6PVeDG9zPVKLuLeg</id>
    <link href="https://mp.weixin.qq.com/s/C663GI6PVeDG9zPVKLuLeg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>聚焦ASH 2020：四项有望改变实践的重要研究</title>
    <updated>2020-12-04T09:39:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-04:/s/mWIPVJq88z7zsrsQ1IfiPw</id>
    <link href="https://mp.weixin.qq.com/s/mWIPVJq88z7zsrsQ1IfiPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年11月│失败临床研究TOP5</title>
    <updated>2020-12-02T13:47:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-02:/s/w-s96H9MjXvPDP6bT8Sy5w</id>
    <link href="https://mp.weixin.qq.com/s/w-s96H9MjXvPDP6bT8Sy5w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>晚期NSCLC一线免疫治疗「图鉴」​</title>
    <updated>2020-11-30T12:08:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-30:/s/EExN1u2TnSZz40fah6pGog</id>
    <link href="https://mp.weixin.qq.com/s/EExN1u2TnSZz40fah6pGog" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>